Upper Limb Motor DysfunctionNCT07739264
ZEPU-SGI1PLUS Hand Training Study (ZEPUSGI1RCT)
A study testing ZEPU-SG1PLUS Hand Functional Comprehensive Training System and Standard-of-Care Rehabilitation in people with Upper Limb Motor Dysfunction and Stroke, run by Bangladesh Medical University at 1 site in Bangladesh.
Trial summary
The goal of this pilot randomized controlled trial is to learn whether the ZEPU-SG1PLUS Hand Functional Comprehensive Training System - a robotic device used alongside standard rehabilitation - is safe, feasible, and helpful for people with upper limb (arm/hand) motor problems caused by stroke, incomplete spinal cord… Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Upper Limb Motor Dysfunction, Stroke, Incomplete Spinal Cord Injury
- What is being tested?
- ZEPU-SG1PLUS Hand Functional Comprehensive Training System and Standard-of-Care Rehabilitation
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 36 participants
- Where
- 1 siteBangladesh
- Study dates
- 1 Jul 2026to Nov 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Presence of upper-limb motor dysfunction, with or without concurrent lower-limb impairment, due to one of the following conditions: (a) stroke, with onset between 2 and 24 months prior to enrollment; (b) incomplete spinal cord injury (neurological level C5 and below), classified as ASIA Impairment Scale C or D; (c) traumatic brain injury with persistent upper-limb functional limitation; or (d) orthopedic or post-surgical conditions involving the shoulder, elbow, wrist, or hand with persistent functional impairment for > 3 months
- Age between 18 and 60 years, inclusive
- Ability to understand study procedures and follow instructions, and to provide written informed consent (or assent with guardian consent where applicable)
- Body weight and limb anthropometry compatible with the ZEPU-SG1PLUS Hand Functional Comprehensive Training System per manufacturer specifications
- Medically stable and cleared by a physician for robotic rehabilitation, with no active infection, uncontrolled cardiac or respiratory disease, severe osteoporosis, uncontrolled epilepsy, or untreated deep vein thrombosis
Who cannot join
- Complete spinal cord injury or profound motor paralysis preventing safe interaction with robotic devices
- Severe cognitive impairment, defined as a Mini-Mental State Examination (MMSE) score < 24, that would compromise safe participation
- Severe spasticity of the upper limb, defined as a Modified Ashworth Scale score > 3
- Unstable fractures, severe fixed joint contractures of the shoulder, elbow, wrist, or hand (e.g., > 30°), or severe pain limiting safe robotic training
- Uncontrolled cardiac arrhythmia, presence of a pacemaker, or other implanted electronic medical device incompatible with robotic sensors
- Pregnancy
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Bangladesh1 site, 1 recruiting
- Recruiting
Bangladesh Medical University
Dhaka, 1000
Md. Abdus Shakoor, Ph.D., +8801819410080, shakoorma@bmu.ac.bd
About this study
Official title: Feasibility, Safety and Efficacy of ZEPU-SGI1PLUS Hand Functional Comprehensive Training Systems in Patients With Upper Limb Motor Dysfunction
The goal of this pilot randomized controlled trial is to learn whether the ZEPU-SG1PLUS Hand Functional Comprehensive Training System - a robotic device used alongside standard rehabilitation - is safe, feasible, and helpful for people with upper limb (arm/hand) motor problems caused by stroke, incomplete spinal cord injury, traumatic brain injury, or orthopedic conditions.
The main questions it aims to answer are:
Read more
Is robotic-assisted hand training well tolerated by patients, and can it be safely added to standard rehabilitation, with acceptable rates of device-related side effects? Does adding robotic hand training to standard rehabilitation improve arm and hand strength, range of motion, and functional ability compared with standard rehabilitation alone? Is it practical to fit this type of robotic training into everyday rehabilitation services at Bangladesh Medical University?
Researchers will compare a robotic-augmented rehabilitation group to a standard-care (control) group to see whether adding robotic hand training works better than usual rehabilitation alone.
Participants will:
Be randomly assigned to one of two groups: one receiving standard rehabilitation plus robotic hand training with the ZEPU-SG1PLUS device, and one receiving standard rehabilitation alone If assigned to the robotic training group, attend three training sessions per week for 12 weeks, each lasting about 30-45 minutes, at the Robotic Rehabilitation Centre, BMU Undergo assessments at the start of the study and at two-week intervals during the 12-week program and follow-up period, including tests of muscle strength, joint movement, hand function, and daily activity ability Be monitored throughout for any side effects or safety concerns related to the training
Read the detailed description
Upper limb motor dysfunction following stroke, incomplete spinal cord injury, traumatic brain injury, and orthopedic conditions is a major contributor to long-term disability. Conventional rehabilitation, while foundational, is often limited in the intensity, repetition, and task specificity needed to optimally drive neuroplasticity-dependent motor recovery. Electromechanical and robotic rehabilitation systems have emerged as adjuncts capable of delivering standardized, repetitive, programmable movement training with real-time feedback and objective performance monitoring, and evidence from high-income settings suggests such systems can improve motor function and functional outcomes when combined with conventional therapy. However, data on the feasibility, safety, and effectiveness of these technologies in low- and middle-income country (LMIC) settings, including Bangladesh, remain limited.
Bangladesh Medical University (BMU) has recently introduced the ZEPU-SG1PLUS Hand Functional Comprehensive Training System at its Robotic Rehabilitation Centre. Before this technology is integrated more broadly into clinical practice, this pilot study will generate foundational local evidence on its feasibility, safety, and preliminary efficacy, and will inform the design and sample-size estimation of a future adequately powered randomized controlled trial.
Device: The ZEPU-SG1PLUS is a non-powered, mechanically assisted training system built around a stable steel-frame table integrated with twelve dedicated training modules targeting distinct hand and upper-limb movement patterns, including thumb-to-palm motion, wrist flexion-extension, forearm rotation, finger flexion/extension, pinching, side pinching, spherical grip rotation, ulnar/radial deviation, horizontal stretching, and hand lifting. Resistance is provided by an adjustable counterweight system (four independent columns, 250 g increments, 500 g-3000 g range), allowing progressive, individualized resistance training. A tablet-based interactive software interface supports user identification, session setup, timing control, and recording of training activity, with session duration configurable from 1-99 minutes.
Design: This is a pilot randomized controlled trial conducted at the Robotic Rehabilitation Centre, Department of Physical Medicine and Rehabilitation, BMU. Eligible participants (adults with upper-limb motor dysfunction due to stroke, incomplete spinal cord injury, traumatic brain injury, or orthopaedic/post-surgical conditions) will be randomly allocated 1:1 to an Intervention Arm (standard-of-care rehabilitation plus ZEPU-SG1PLUS training) or a Control Arm (standard-of-care rehabilitation alone). Robotic sessions will be delivered 3 times weekly for 12 weeks (30-45 minutes per session), under supervision of physiatrists and physiotherapists, with training parameters progressively adjusted based on individual performance and tolerance. Assessments occur at baseline and at two-week intervals through the intervention and follow-up periods.
Assessment methods: Muscle strength is assessed by Manual Muscle Testing, grip strength by dynamometer, spasticity by the Modified Ashworth Scale, and general health status by the EQ-VAS. Device-recorded training parameters (e.g., repetitions, resistance level, session duration) are captured as objective indicators of rehabilitation progress. Feasibility and usability are evaluated through screening/enrollment flow, session adherence and dropout tracking, therapist training and device set-up time, level of assistance required for donning/doffing, and a Post-Study System Usability Questionnaire administered at study completion.
Safety monitoring: Pre-session screening of vital signs and skin integrity, use of a safety harness/tracking system during initial sessions, continuous therapist supervision, post-session skin and fatigue checks, and an emergency-stop mechanism on the device are built into the protocol. All adverse events and serious adverse events are recorded and reported to the safety monitor and the BMU Institutional Review Board.
Statistical analysis: Descriptive statistics will summarize safety outcomes (AEs/SAEs, adherence, dropouts). Continuous efficacy variables will be summarized as mean ± SD (or median/IQR for non-normal data) at each time point, with paired/unpaired t-tests or Wilcoxon signed-rank tests used to compare baseline versus follow-up findings as appropriate. The primary analysis will follow an intention-to-treat approach including all randomized participants, with a secondary per-protocol analysis restricted to those completing the intervention per protocol; missing follow-up data will be handled using group-wise mean substitution. A two-tailed p-value < 0.05 will be considered statistically significant. Analyses will be performed using SPSS.
- Conditions
- Upper Limb Motor Dysfunction, Stroke, Incomplete Spinal Cord Injury, Traumatic Brain Injury, Upper Limb Orthopedic Trauma
- Being tested
- ZEPU-SG1PLUS Hand Functional Comprehensive Training System, Standard-of-Care Rehabilitation
- Keywords
- Robotic Rehabilitation, ZEPU-SG1PLUS, Hand Function Training, Neurorehabilitation, Musculoskeletal Rehabilitation
- Medical subject headings
- Stroke, Brain Injuries, Traumatic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ZEPU-SG1PLUS Hand Functional Comprehensive Training SystemDevice
A non-powered, mechanically assisted robotic training device for the hand and upper limb, incorporating twelve dedicated training modules (e.g., thumb-to-palm motion, wrist flexion-extension, forearm rotation, finger flexion/extension, pinching, grip rotation) with an adjustable counterweight resistance system (500g-3000g). Administered 3 sessions/week for 12 weeks (30-45 minutes/session) in addition to standard-of-care rehabilitation.
Standard-of-Care RehabilitationOther
Standard rehabilitation program including conventional therapeutic exercise and wax bath therapy, delivered per institutional protocol at the Department of Physical Medicine and Rehabilitation, BMU, without the addition of robotic-assisted training.
| Study group | Role | What they receive |
|---|---|---|
| Robotic-Augmented Rehabilitation Group | Experimental | Participants receive standard-of-care rehabilitation combined with robotic-assisted hand training using the ZEPU-SG1PLUS Hand Functional Comprehensive Training System, 3 sessions per week for 12 weeks (approximately 30-45 minutes per session). Receives: Device: ZEPU-SG1PLUS Hand Functional Comprehensive Training System; Other: Standard-of-Care Rehabilitation |
| Standard Care (Control) Group | Active comparator | Participants receive standard-of-care rehabilitation alone, including conventional exercise and wax bath therapy, without the addition of robotic-assisted hand training. Receives: Other: Standard-of-Care Rehabilitation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Device-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)
Number and proportion of participants experiencing device-related AEs or SAEs, including falls, skin breakdown/pressure sores, joint pain or injury, cardiovascular events, fracture, or device malfunction.
Measured: Baseline (Week 0) through end of 12-week intervention and follow-up
Device Tolerability (Session Completion Rate)
Number of robotic training sessions completed relative to sessions planned; number of participant drop-outs and reasons for drop-out.
Measured: 12 weeks
Secondary outcomes (4)
Muscle Strength
Assessed using Manual Muscle Testing (MMT).
Measured: Baseline and every 2 weeks through 12 weeks
Grip Strength
Assessed using a hand-held dynamometer.
Measured: Baseline and every 2 weeks through 12 weeks
Upper-Limb Spasticity
Assessed using the Modified Ashworth Scale (MAS), a clinician-rated measure of resistance to passive muscle stretch, scored from 0 (no increase in muscle tone) to 4 (limb rigid in flexion or extension), with higher scores indicating greater spasticity (worse outcome).
Measured: Baseline and every 2 weeks through 12 weeks
Health-Related Quality of Life
Health-related quality of life assessed using the EQ Visual Analogue Scale (EQ-VAS), a self-rated measure of current health status on a vertical scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state), with higher scores indicating better health-related quality of life.
Measured: Baseline and every 2 weeks up to 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jul 2026
- Study start1 Jul 2026
- Primary completionSep 2026 (estimated)
- Study completionNov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Upper Limb Motor DysfunctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 36 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Bangladesh Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Md. Abdus Shakoor, Ph.D., Bangladesh Medical University
- Investigators
- Md. Abdus Shakoor, Ph.D., Principal investigator, Bangladesh Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07739264
- Sponsor's protocol ID
- PR-1434
- Status last verified
- Jul 2026
- First submitted
- 27 Jul 2026
- Last updated
- 11 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility, Safety and Efficacy of ZEPU-SGI1PLUS Hand Functional Comprehensive Training Systems in Patients With Upper Limb Motor Dysfunction
- ClinicalTrials.gov ID
- NCT07739264
- Acronym / sponsor ID
- PR-1434
- Conditions
- Upper Limb Motor Dysfunction, Stroke, Incomplete Spinal Cord Injury, Traumatic Brain Injury, Upper Limb Orthopedic Trauma
- Keywords
- Robotic Rehabilitation, ZEPU-SG1PLUS, Hand Function Training, Neurorehabilitation, Musculoskeletal Rehabilitation
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 36 participants (estimated)
- Lead sponsor
- Bangladesh Medical UniversityUniversity, hospital or other
- Study start
- 1 Jul 2026 (actual)
- Primary completion
- Sep 2026 (estimated)
- Study completion
- Nov 2026 (estimated)
- First posted
- 31 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this pilot randomized controlled trial is to learn whether the ZEPU-SG1PLUS Hand Functional Comprehensive Training System - a robotic device used alongside standard rehabilitation - is safe, feasible, and helpful for people with upper limb (arm/hand) motor problems caused by stroke, incomplete spinal cord injury, traumatic brain injury, or orthopedic conditions.
The main questions it aims to answer are:
Is robotic-assisted hand training well tolerated by patients, and can it be safely added to standard rehabilitation, with acceptable rates of device-related side effects? Does adding robotic hand training to standard rehabilitation improve arm and hand strength, range of motion, and functional ability compared with standard rehabilitation alone? Is it practical to fit this type of robotic training into everyday rehabilitation services at Bangladesh Medical University?
Researchers will compare a robotic-augmented rehabilitation group to a standard-care (control) group to see whether adding robotic hand training works better than usual rehabilitation alone.
Participants will:
Be randomly assigned to one of two groups: one receiving standard rehabilitation plus robotic hand training with the ZEPU-SG1PLUS device, and one receiving standard rehabilitation alone If assigned to the robotic training group, attend three training sessions per week for 12 weeks, each lasting about 30-45 minutes, at the Robotic Rehabilitation Centre, BMU Undergo assessments at the start of the study and at two-week intervals during the 12-week program and follow-up period, including tests of muscle strength, joint movement, hand function, and daily activity ability Be monitored throughout for any side effects or safety concerns related to the training
Detailed description
Upper limb motor dysfunction following stroke, incomplete spinal cord injury, traumatic brain injury, and orthopedic conditions is a major contributor to long-term disability. Conventional rehabilitation, while foundational, is often limited in the intensity, repetition, and task specificity needed to optimally drive neuroplasticity-dependent motor recovery. Electromechanical and robotic rehabilitation systems have emerged as adjuncts capable of delivering standardized, repetitive, programmable movement training with real-time feedback and objective performance monitoring, and evidence from high-income settings suggests such systems can improve motor function and functional outcomes when combined with conventional therapy. However, data on the feasibility, safety, and effectiveness of these technologies in low- and middle-income country (LMIC) settings, including Bangladesh, remain limited.
Bangladesh Medical University (BMU) has recently introduced the ZEPU-SG1PLUS Hand Functional Comprehensive Training System at its Robotic Rehabilitation Centre. Before this technology is integrated more broadly into clinical practice, this pilot study will generate foundational local evidence on its feasibility, safety, and preliminary efficacy, and will inform the design and sample-size estimation of a future adequately powered randomized controlled trial.
Device: The ZEPU-SG1PLUS is a non-powered, mechanically assisted training system built around a stable steel-frame table integrated with twelve dedicated training modules targeting distinct hand and upper-limb movement patterns, including thumb-to-palm motion, wrist flexion-extension, forearm rotation, finger flexion/extension, pinching, side pinching, spherical grip rotation, ulnar/radial deviation, horizontal stretching, and hand lifting. Resistance is provided by an adjustable counterweight system (four independent columns, 250 g increments, 500 g-3000 g range), allowing progressive, individualized resistance training. A tablet-based interactive software interface supports user identification, session setup, timing control, and recording of training activity, with session duration configurable from 1-99 minutes.
Design: This is a pilot randomized controlled trial conducted at the Robotic Rehabilitation Centre, Department of Physical Medicine and Rehabilitation, BMU. Eligible participants (adults with upper-limb motor dysfunction due to stroke, incomplete spinal cord injury, traumatic brain injury, or orthopaedic/post-surgical conditions) will be randomly allocated 1:1 to an Intervention Arm (standard-of-care rehabilitation plus ZEPU-SG1PLUS training) or a Control Arm (standard-of-care rehabilitation alone). Robotic sessions will be delivered 3 times weekly for 12 weeks (30-45 minutes per session), under supervision of physiatrists and physiotherapists, with training parameters progressively adjusted based on individual performance and tolerance. Assessments occur at baseline and at two-week intervals through the intervention and follow-up periods.
Assessment methods: Muscle strength is assessed by Manual Muscle Testing, grip strength by dynamometer, spasticity by the Modified Ashworth Scale, and general health status by the EQ-VAS. Device-recorded training parameters (e.g., repetitions, resistance level, session duration) are captured as objective indicators of rehabilitation progress. Feasibility and usability are evaluated through screening/enrollment flow, session adherence and dropout tracking, therapist training and device set-up time, level of assistance required for donning/doffing, and a Post-Study System Usability Questionnaire administered at study completion.
Safety monitoring: Pre-session screening of vital signs and skin integrity, use of a safety harness/tracking system during initial sessions, continuous therapist supervision, post-session skin and fatigue checks, and an emergency-stop mechanism on the device are built into the protocol. All adverse events and serious adverse events are recorded and reported to the safety monitor and the BMU Institutional Review Board.
Statistical analysis: Descriptive statistics will summarize safety outcomes (AEs/SAEs, adherence, dropouts). Continuous efficacy variables will be summarized as mean ± SD (or median/IQR for non-normal data) at each time point, with paired/unpaired t-tests or Wilcoxon signed-rank tests used to compare baseline versus follow-up findings as appropriate. The primary analysis will follow an intention-to-treat approach including all randomized participants, with a secondary per-protocol analysis restricted to those completing the intervention per protocol; missing follow-up data will be handled using group-wise mean substitution. A two-tailed p-value < 0.05 will be considered statistically significant. Analyses will be performed using SPSS.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Robotic-Augmented Rehabilitation Group | Experimental | Device: ZEPU-SG1PLUS Hand Functional Comprehensive Training System, Other: Standard-of-Care RehabilitationParticipants receive standard-of-care rehabilitation combined with robotic-assisted hand training using the ZEPU-SG1PLUS Hand Functional Comprehensive Training System, 3 sessions per week for 12 weeks (approximately 30-45 minutes per session). |
| Standard Care (Control) Group | Active comparator | Other: Standard-of-Care RehabilitationParticipants receive standard-of-care rehabilitation alone, including conventional exercise and wax bath therapy, without the addition of robotic-assisted hand training. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Presence of upper-limb motor dysfunction, with or without concurrent lower-limb impairment, due to one of the following conditions: (a) stroke, with onset between 2 and 24 months prior to enrollment; (b) incomplete spinal cord injury (neurological level C5 and below), classified as ASIA Impairment Scale C or D; (c) traumatic brain injury with persistent upper-limb functional limitation; or (d) orthopedic or post-surgical conditions involving the shoulder, elbow, wrist, or hand with persistent functional impairment for > 3 months
- Age between 18 and 60 years, inclusive
- Ability to understand study procedures and follow instructions, and to provide written informed consent (or assent with guardian consent where applicable)
- Body weight and limb anthropometry compatible with the ZEPU-SG1PLUS Hand Functional Comprehensive Training System per manufacturer specifications
- Medically stable and cleared by a physician for robotic rehabilitation, with no active infection, uncontrolled cardiac or respiratory disease, severe osteoporosis, uncontrolled epilepsy, or untreated deep vein thrombosis
Key exclusion criteria (6 listed)
- Complete spinal cord injury or profound motor paralysis preventing safe interaction with robotic devices
- Severe cognitive impairment, defined as a Mini-Mental State Examination (MMSE) score < 24, that would compromise safe participation
- Severe spasticity of the upper limb, defined as a Modified Ashworth Scale score > 3
- Unstable fractures, severe fixed joint contractures of the shoulder, elbow, wrist, or hand (e.g., > 30°), or severe pain limiting safe robotic training
- Uncontrolled cardiac arrhythmia, presence of a pacemaker, or other implanted electronic medical device incompatible with robotic sensors
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ZEPU-SG1PLUS Hand Functional Comprehensive Training SystemA non-powered, mechanically assisted robotic training device for the hand and upper limb, incorporating twelve dedicated training modules (e.g., thumb-to-palm motion, wrist flexion-extension, forearm rotation, finger flexion/extension, pinching, grip rotation) with an adjustable counterweight resistance system (500g-3000g). Administered 3 sessions/week for 12 weeks (30-45 minutes/session) in addition to standard-of-care rehabilitation. | Device | Robotic-Augmented Rehabilitation Group |
| Standard-of-Care RehabilitationStandard rehabilitation program including conventional therapeutic exercise and wax bath therapy, delivered per institutional protocol at the Department of Physical Medicine and Rehabilitation, BMU, without the addition of robotic-assisted training. | Other | Robotic-Augmented Rehabilitation Group, Standard Care (Control) Group |
Primary outcome
Incidence of Device-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Baseline (Week 0) through end of 12-week intervention and follow-up
Number and proportion of participants experiencing device-related AEs or SAEs, including falls, skin breakdown/pressure sores, joint pain or injury, cardiovascular events, fracture, or device malfunction.
Device Tolerability (Session Completion Rate)
Time frame: 12 weeks
Number of robotic training sessions completed relative to sessions planned; number of participant drop-outs and reasons for drop-out.
4 secondary outcomes
Muscle Strength
Time frame: Baseline and every 2 weeks through 12 weeks
Grip Strength
Time frame: Baseline and every 2 weeks through 12 weeks
Upper-Limb Spasticity
Time frame: Baseline and every 2 weeks through 12 weeks
Health-Related Quality of Life
Time frame: Baseline and every 2 weeks up to 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Upper Limb Motor Dysfunction
Not yet recruiting
PhiCube for Bilateral Upper Limb Neuromotor and Cognitive Rehabilitation in Adults
Stroke, Parkinson Disease
Recruiting
ZEPU-2000 Limb Rehabilitation Trainer Study (ZEPU2000RCT)
Stroke, Incomplete Spinal Cord Injury (SCI)
Recruiting
ZEPU-AI Series Limb Feedback Robot Training Study (ZEPUAISRCT)
Stroke, Spinal Cord Injuries
Not yet recruiting
Mirror Therapy in Children With Hemiparetic Cerebral Palsy
Hemiplegic Cerebral Palsy, Mirror Hands
Not yet recruiting
Spinal Cord Stimulation Combined With Motor Imagery Brain-Computer Interface for Chronic Post-Stroke Upper Limb Motor Dysfunction
Chronic Stroke
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Md. Abdus Shakoor, Ph.D. principal investigator
Bangladesh Medical University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing ZEPU-SG1PLUS Hand Functional Comprehensive Training System and Standard-of-Care Rehabilitation in people with Upper Limb Motor Dysfunction and Stroke, run by Bangladesh Medical University at 1 site in Bangladesh.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Bangladesh. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Md. Abdus Shakoor, Ph.D. (+8801819410080, shakoorma@bmu.ac.bd), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Device-Related Adverse Events (AEs) and Serious Adverse Events (SAEs) (time frame: Baseline (Week 0) through end of 12-week intervention and follow-up). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2026.